Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1744993

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1744993

Avian Influenza Vaccine

PUBLISHED:
PAGES: 286 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Avian Influenza Vaccine Market to Reach US$1.9 Billion by 2030

The global market for Avian Influenza Vaccine estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Inactivated Vaccine, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$800.9 Million by the end of the analysis period. Growth in the Live Attenuated Vaccine segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$352.5 Million While China is Forecast to Grow at 10.8% CAGR

The Avian Influenza Vaccine market in the U.S. is estimated at US$352.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$402.1 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Avian Influenza Vaccine Market - Key Trends & Drivers Summarized

Why Are Avian Influenza Vaccines Gaining Strategic Relevance in Biosecurity, Poultry Health Management, and Food Supply Stability?

Avian influenza vaccines are emerging as a vital line of defense in global poultry health management as highly pathogenic avian influenza (HPAI) outbreaks continue to disrupt poultry production, cross-border trade, and food security. The escalating frequency and geographic spread of HPAI strains-such as H5N1 and H5N8-have underscored the need for vaccination strategies that go beyond culling and movement restrictions. Vaccines are being viewed not only as a disease control tool but also as a risk mitigation strategy that supports long-term continuity of supply in the global poultry value chain.

The economic losses linked to avian influenza outbreaks are significant, impacting commercial poultry producers, smallholder farms, and national economies reliant on poultry exports. Mass mortality events, reduced egg production, and supply chain disruptions necessitate preemptive disease prevention approaches. Vaccination offers a cost-effective solution that helps preserve flock immunity, minimize transmission, and protect against zoonotic spillover. With growing concerns over pandemic preparedness, governments are beginning to prioritize strategic vaccine stockpiling and targeted immunization programs for high-risk zones.

Moreover, the role of avian influenza vaccines has gained renewed urgency as One Health frameworks emphasize the interconnectedness of animal health, human health, and environmental resilience. Vaccination campaigns are increasingly being integrated with surveillance programs and genetic sequencing to track viral evolution and adapt immunization strategies accordingly. As the poultry sector faces mounting pressure to ensure biosecurity, maintain animal welfare standards, and safeguard protein availability, vaccines are becoming central to the global response infrastructure.

How Are Vaccine Technologies, Strain Matching, and Delivery Platforms Advancing Efficacy and Deployment?

Vaccine development for avian influenza is evolving rapidly, with both inactivated and recombinant technologies gaining prominence. Inactivated whole-virus vaccines remain the most widely used due to their proven safety and broad immunogenicity, particularly in endemic regions. However, newer recombinant vector vaccines-utilizing platforms such as fowlpox, Newcastle disease virus (NDV), and herpesvirus of turkeys (HVT)-are enabling differentiated immune responses, DIVA (Differentiating Infected from Vaccinated Animals) compliance, and easier adaptation to emerging viral strains.

Strain matching remains a critical challenge in vaccine effectiveness, as antigenic drift and reassortment frequently render existing vaccines less protective. Manufacturers are leveraging reverse genetics and genomic surveillance data to accelerate the development of strain-specific or multivalent vaccines. These approaches enable rapid customization and regulatory alignment, particularly in regions prone to variant emergence. Efforts are also underway to develop broad-spectrum or “universal” avian influenza vaccines capable of offering cross-protection against multiple subtypes.

Vaccine delivery platforms are also advancing, with injectable, spray, and in-ovo administration techniques supporting scalable immunization across different poultry species and production systems. Automated delivery systems and thermostable formulations are improving efficiency in large-scale farms, while heat-tolerant, needle-free options are being deployed in resource-limited or remote areas. The integration of vaccination with digital monitoring tools and flock-level immunization analytics is enhancing tracking and compliance in both commercial and government-led programs.

Which Poultry Segments, Production Systems, and Regional Priorities Are Driving Vaccine Demand?

Commercial layer and broiler operations are the primary users of avian influenza vaccines, given their exposure to high-density farming conditions, rapid bird turnover, and economic sensitivity to disease outbreaks. Breeder flocks and grandparent stock are also prioritized for vaccination to maintain supply chain continuity and ensure vertical protection. In contrast, backyard poultry and live bird markets, which often act as reservoirs for viral persistence, are becoming focal points for targeted government interventions and pilot vaccination programs.

Free-range and organic poultry production systems-where birds have outdoor access and higher environmental exposure-are driving increased interest in preventive vaccination. These systems are at higher risk of contact with migratory birds and wild reservoirs, making proactive immunization critical for disease prevention. In regions where culling is politically or economically unviable, such as Southeast Asia, Latin America, and parts of Africa, vaccines are being deployed as a frontline control measure in both commercial and village-level operations.

Regionally, Asia-Pacific continues to lead in avian influenza vaccine consumption due to recurring HPAI outbreaks, dense poultry populations, and longstanding vaccine integration in disease control policies. China, Vietnam, Indonesia, and India have institutionalized vaccine use as part of national biosecurity frameworks. Europe is witnessing renewed adoption amid HPAI resurgence in commercial flocks and wild birds, while North America is cautiously evaluating vaccination alongside enhanced surveillance. Latin America and the Middle East are expanding their vaccination capacity to protect export-oriented poultry sectors and mitigate cross-border transmission risk.

How Are Regulatory Frameworks, Surveillance Synergies, and Trade Considerations Shaping Market Evolution?

Global regulatory agencies, including the OIE (now WOAH) and FAO, are increasingly recognizing the role of vaccines as part of holistic avian influenza management. Countries are implementing risk-based vaccination policies guided by surveillance data, regional risk mapping, and genetic sequencing. Regulatory harmonization, particularly around DIVA-compliant vaccines, is allowing countries to maintain trade transparency while deploying immunization in outbreak-prone zones.

Surveillance and vaccine deployment are becoming interlinked, with integrated systems supporting real-time data collection, serological monitoring, and vaccine impact assessment. Genomic tools are enabling early detection of mutations that may impact vaccine efficacy, prompting timely reformulations. These synergies are helping authorities make informed decisions on vaccination timing, coverage, and withdrawal, minimizing both epidemiological and economic fallout from poorly matched immunization campaigns.

Trade dynamics remain a complex variable in the vaccine equation. Historically, vaccination has triggered export restrictions due to concerns over disease masking and traceability. However, this stance is shifting as science-based frameworks and DIVA strategies gain global traction. Countries are increasingly seeking trade-friendly vaccination protocols that allow for continued market access while ensuring domestic outbreak control. The evolution of trade policy will play a pivotal role in vaccine adoption strategies, particularly for export-reliant poultry economies.

What Role Do Public-Private Partnerships, Emergency Stockpiling, and R&D Pipelines Play in Strengthening Vaccine Readiness?

Public-private partnerships are proving essential in scaling production capacity, improving cold chain logistics, and advancing R&D. Governments are collaborating with animal health companies to secure vaccine stockpiles, accelerate field trials, and build surge manufacturing capability in the event of zoonotic spillover or large-scale outbreaks. These partnerships also facilitate knowledge transfer, regulatory alignment, and joint funding of platform technologies with cross-pathogen utility.

Emergency preparedness is gaining momentum, with countries developing national vaccine banks and outbreak response protocols. Strategic reserves of inactivated and vector-based vaccines are being maintained for rapid deployment in containment zones. Simulation exercises and vaccine distribution drills are enhancing readiness and inter-agency coordination across agriculture, public health, and veterinary sectors. Multilateral initiatives such as the World Bank’s pandemic response frameworks are further integrating avian influenza vaccines into national biosecurity roadmaps.

The R&D pipeline is diversifying, with candidates targeting improved cross-protection, thermostability, and single-dose efficacy. Research is also underway into mRNA-based avian influenza vaccines, leveraging lessons from human vaccine platforms to enhance speed and adaptability. With avian influenza remaining a high-priority zoonosis under One Health mandates, continued investment in vaccine innovation is expected to play a decisive role in global disease preparedness strategies.

What Are the Factors Driving Growth in the Avian Influenza Vaccine Market?

The avian influenza vaccine market is gaining traction as poultry sector vulnerabilities, zoonotic risk awareness, and global food security imperatives converge to reshape disease control priorities. Vaccines are no longer viewed as last-resort tools but as foundational elements of integrated, science-driven animal health management.

Key growth drivers include recurring outbreaks of high-pathogenicity strains, regulatory acceptance of vaccination in trade-sensitive contexts, technological advancements in strain-matched and DIVA-compliant formulations, and expanding poultry production in high-risk regions. Public sector readiness initiatives and private sector R&D efforts are jointly reinforcing market momentum across geographies and poultry types.

As avian influenza evolves under migratory, agricultural, and climatic pressures, could vaccine-enabled resilience redefine how the world safeguards poultry supply chains and prepares for the next zoonotic frontier?

SCOPE OF STUDY:

The report analyzes the Avian Influenza Vaccine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Inactivated, Live Attenuated, Recombinant, Vector-based, Other Types); Application (Chicken, Duck, Goose, Turkey, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • AstraZeneca
  • Bayer AG
  • Bimeda Inc.
  • Boehringer Ingelheim GmbH
  • Ceva Sante Animale
  • CSL Seqirus
  • Elanco Animal Health
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc (GSK)
  • HIPRA
  • ID Biomedical Corporation
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals
  • Medion
  • Merck & Co., Inc.
  • Microgen
  • Moderna, Inc.
  • Novartis AG
  • Novavax, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP34670

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Avian Influenza Vaccine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Poultry Outbreaks and Cross-Species Transmission Risks Throw the Spotlight on Avian Influenza Vaccines
    • Growth in Poultry Production and Biosecurity Regulations Spurs Vaccine Adoption Across Commercial Farms
    • OEM Advancements in Recombinant and Inactivated Vaccine Technologies Strengthen Response Against Emerging Strains
    • Expansion of Government-Led Vaccination Programs in High-Risk Regions Supports Market Penetration
    • Use of DIVA (Differentiating Infected from Vaccinated Animals) Vaccines Enhances Surveillance and Control Efforts
    • Integration of Rapid Diagnostics and Cold Chain Logistics Enables Scalable and Targeted Immunization
    • Global Focus on Pandemic Prevention and Zoonotic Disease Control Supports R&D Funding for Poultry Vaccines
    • Adoption of Mass Administration Tools Including Spray and Drinking Water Routes Improves Efficiency
    • Growth in Demand for Organic and Antibiotic-Free Poultry Drives Reliance on Preventive Vaccination
    • OEM Collaboration With Veterinary Authorities Supports Strain-Specific and Regionally Adapted Vaccine Solutions
    • Monitoring of Wild Bird Populations and Migratory Routes Fuels Preemptive Vaccination Strategies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Avian Influenza Vaccine Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Avian Influenza Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Avian Influenza Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Vector-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Vector-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Vector-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Chicken by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Chicken by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Chicken by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Duck by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Duck by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Duck by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Goose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Goose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Goose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Turkey by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Turkey by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Turkey by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • JAPAN
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • CHINA
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • EUROPE
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Avian Influenza Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Avian Influenza Vaccine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • FRANCE
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • GERMANY
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Germany 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Italy 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: UK 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Spain 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Russia 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of Europe 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Avian Influenza Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Avian Influenza Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Australia 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • INDIA
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: India 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: South Korea 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Avian Influenza Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Avian Influenza Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Argentina 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Brazil 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Mexico 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Latin America 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Avian Influenza Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Avian Influenza Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Iran 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Israel 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Saudi Arabia 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: UAE 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Middle East 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030
  • AFRICA
    • Avian Influenza Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Avian Influenza Vaccine by Type - Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Avian Influenza Vaccine by Type - Percentage Breakdown of Value Sales for Inactivated, Live Attenuated, Recombinant, Vector-based and Other Types for the Years 2015, 2025 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Avian Influenza Vaccine by Application - Other Applications, Chicken, Duck, Goose and Turkey Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Africa 15-Year Perspective for Avian Influenza Vaccine by Application - Percentage Breakdown of Value Sales for Other Applications, Chicken, Duck, Goose and Turkey for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!